Simulations Plus (NASDAQ:SLP) Releases FY 2026 Earnings Guidance

Simulations Plus (NASDAQ:SLP) updated its FY 2026 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 1.030-1.100 for the period, compared to the consensus estimate of 1.000. The company issued revenue guidance of $79.0 million-$82.0 million, compared to the consensus revenue estimate of $80.5 million.

Wall Street Analysts Forecast Growth

SLP has been the topic of a number of recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Simulations Plus in a research note on Wednesday, October 8th. KeyCorp reissued a “sector weight” rating on shares of Simulations Plus in a research note on Wednesday, October 29th. BTIG Research cut shares of Simulations Plus from a “buy” rating to a “neutral” rating in a research note on Thursday, December 18th. TD Cowen reaffirmed a “hold” rating on shares of Simulations Plus in a report on Thursday, January 8th. Finally, Citigroup reissued a “market perform” rating on shares of Simulations Plus in a report on Tuesday, January 6th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $25.00.

Simulations Plus Stock Performance

Shares of SLP traded down $0.85 during midday trading on Friday, hitting $16.86. 119,202 shares of the company traded hands, compared to its average volume of 342,922. The stock has a market cap of $339.71 million, a price-to-earnings ratio of -5.27 and a beta of 1.09. The firm has a 50 day moving average of $19.04 and a 200-day moving average of $16.48. Simulations Plus has a 52 week low of $12.39 and a 52 week high of $37.67.

Simulations Plus (NASDAQ:SLP) last posted its earnings results on Thursday, January 8th. The technology company reported $0.13 EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.05). The firm had revenue of $18.42 million during the quarter, compared to analysts’ expectations of $18.05 million. Simulations Plus had a positive return on equity of 14.02% and a negative net margin of 81.66%.During the same quarter in the prior year, the firm posted $0.17 earnings per share. Sell-side analysts predict that Simulations Plus will post 1.09 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Simulations Plus

Institutional investors have recently bought and sold shares of the business. First Light Asset Management LLC bought a new stake in shares of Simulations Plus during the 2nd quarter worth approximately $6,232,000. Squarepoint Ops LLC increased its stake in Simulations Plus by 522.1% in the third quarter. Squarepoint Ops LLC now owns 220,103 shares of the technology company’s stock worth $3,317,000 after purchasing an additional 184,725 shares during the period. Ameriprise Financial Inc. lifted its position in shares of Simulations Plus by 25.3% during the second quarter. Ameriprise Financial Inc. now owns 875,447 shares of the technology company’s stock worth $15,277,000 after purchasing an additional 176,747 shares during the last quarter. Bank of America Corp DE boosted its stake in shares of Simulations Plus by 76.7% during the third quarter. Bank of America Corp DE now owns 369,585 shares of the technology company’s stock valued at $5,570,000 after purchasing an additional 160,367 shares during the period. Finally, Marshall Wace LLP grew its holdings in shares of Simulations Plus by 435.9% in the second quarter. Marshall Wace LLP now owns 133,278 shares of the technology company’s stock worth $2,326,000 after purchasing an additional 108,407 shares during the last quarter. Institutional investors own 78.08% of the company’s stock.

Simulations Plus Company Profile

Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.